Subgroup	N	Tau²	Hedges' g	95% CI
Primary model	12	0.12	-0.90	[-1.26, -0.55]
Diagnosis of MDD	5	0.33	-0.93	[-1.87, 0.01]
Exclude open-label	9	0.0000013	-0.81	[-1.03, -0.6]
Exclude high RoB	9	0.084	-0.97	[-1.38, -0.57]
Parallel design	7	0.0000015	-0.80	[-1.11, -0.49]
Crossover or open-label extension	5	0.44	-1.04	[-2.06, -0.03]
Expanded inclusion criteria	15	0.13	-0.88	[-1.21, -0.56]
Excluding outliers	11	0.015	-0.81	[-1.07, -0.55]
Fixed Effects model	12	0.12	-0.84	[-1.02, -0.67]
Alternate dosing in Goodwin 2022	12	0.22	-0.87	[-1.27, -0.47]
Clinician-rated outcomes	7	0.20	-1.02	[-1.6, -0.44]
Self-report outcomes	9	0.48	-1.00	[-1.68, -0.31]